News Sentiment

MESO sentiment intelligence

Mesoblast Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 63 Constructive news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.44 Week of 10 Jul 2026
Weighted tone 63/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+7.4% over one week, +10.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Market Reaction

News confirmed by price

73/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 78/100 classification
One-week reaction 7.4% Price confirming higher
Trend fit Trend inactive 10.8% over four weeks
Fair value 46.7% Materially above fair value
Sentiment-trend disagreement Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 30
Neutral 27
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 9
simplywall.st 7
grafa.com 4
MT Newswires 3
GuruFocus 3
Kalkine Media 3
Simply Wall Street 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Analyst action 7
Guidance 2
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Simply Wall Street Direct company coverage

Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L

Mesoblast (ASX:MSB) shares rose 9.3% after the FDA accepted a modular Biologics License Application (BLA) review for its drug rexlemestrocel-L. The drug aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular as

Tone
Positive 75/100
Event
Market update
Published
03 Jul 2026 17:10
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?

Mesoblast (ASX:MSB) stock is gaining attention after the US FDA accepted its Biologics License Application for rexlemestrocel-L and granted a modular review request for LVAD-related risks, streamlining its approval pathway. Despite recent gains, the stock remains down 26.35% year

Tone
Positive 67/100
Event
Regulatory and legal
Published
02 Jul 2026 05:40
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Mesoblast (ASX:MSB) Stock Forecast & Analyst Predictions

Mesoblast (ASX:MSB) is forecast to achieve significant earnings and revenue growth, with EPS expected to grow by 72.5% and revenue by 38.4% annually. The company has multiple products in development and commercialization, including Ryoncil (FDA-approved) and Rexlemestrocel-L, tar

Tone
Positive 65/100
Event
Earnings
Published
02 Jul 2026 04:10
Source
Simply Wall Street
Stock Titan Direct company coverage

Mesoblast (NASDAQ: MESO) moves rexlemestrocel-L BLA into FDA modular review

Mesoblast Limited (NASDAQ: MESO) announced it has received a Biologics License Application (BLA) filing number from the FDA for its cell therapy rexlemestrocel-L. The company has requested a modular review for the therapy, which aims to prevent life-threatening gastrointestinal b

Tone
Positive 67/100
Event
Market update
Published
01 Jul 2026 09:39
Source
Stock Titan
Market source Direct company coverage

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

Mesoblast Limited has received a Biologics License Application (BLA) filing number from the U.S. FDA for rexlemestrocel-L and requested a modular review. This therapy aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs, an ind

Tone
Positive 73/100
Event
Market update
Published
01 Jul 2026 03:40
Source
Market source
Kalkine Media Direct company coverage

Duratec (ASX:DUR), Elsight (ASX:ELS) and Mesoblast (ASX:MSB): Why These Growth Stocks Are Drawing Market Attention

Duratec (ASX:DUR), Elsight (ASX:ELS), and Mesoblast (ASX:MSB) are attracting significant market attention due to their expanding growth opportunities, substantial insider ownership, and strong operational execution. These companies operate in diverse sectors including infrastruct

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:09
Source
Kalkine Media